Quick answer: latest quarter results, by ticker or company name

Reported Q: Q3 2024 Rev YoY: N/A EPS YoY: -64.7% Move: -2.51%

KalVista Pharmaceuticals

KALV

$15.12 -2.51%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q3 2024

Published: Mar 11, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for KALV

Reported

Report Date

Mar 11, 2024

Quarter Q3 2024

Revenue

N/A

YoY: N/A

EPS

-0.84

YoY: -64.7%

Market Move

-2.51%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

EPS of $-0.84 decreased by 64.7% from previous year
Net income of -29.03M
""Advancing our pipeline efficiently remains our top priority as we leverage our innovative capabilities in the HAE sector." - Andrew McDade, CEO" - Andrew McDade

KALV

KalVista Pharmaceuticals Inc

Period Q3 2024

Currency USD

Report Type Quarterly Earnings

Generated Feb 13, 2026

Executive Summary

KalVista Pharmaceuticals Inc (KALV) reported a net loss of approximately $29 million for Q3 2024, reflecting continued challenges in translating its research and development efforts into commercial success. The company's key products are in various stages of clinical trials, particularly focusing on plasma kallikrein inhibitors for hereditary angioedema (HAE) and diabetic macular edema (DME).

Management signaled a committed focus on advancing clinical trials, particularly the Phase 3 KONFIDENT trial for sebetralstat, a potential on-demand therapy for HAE. While no revenues were reported this quarter, KalVista maintained a robust cash position of $23 million, supported by substantial investment in R&D amounting to $22.5 million, showcasing a focus on innovation despite ongoing operational losses.

Key Performance Indicators

Operating Income

Decreasing

-33.15M

QoQ: -11.45% | YoY: -23.03%

Net Income

Decreasing

-29.03M

QoQ: -4.98% | YoY: -102.54%

EPS

Decreasing

-0.84

QoQ: -5.00% | YoY: -64.71%

Revenue Trend

Margin Analysis

Financial Highlights

### Financial Performance Overview
- Revenue: $0, with significant investment into R&D.
- Net Income: -$29.0 million, translating to an EPS of -$0.84, reflecting a 102.54% decline year-over-year (YoY) and a marginal 4.98% decrease quarter-over-quarter (QoQ).
- Operating Income: -$33.15 million, an 11.45% reduction from the previous quarter, signaling increasing operational inefficiencies.
- Total Operating Expenses: $33.15 million, comprised of R&D ($22.5 million) and general administrative expenses ($10.6 million).

### Ratio Analysis
- Current Ratio: 5.44, indicating a strong liquidity position, far exceeding the industry average.
- Return on Equity (ROE): -32.8%, indicating the firmâ€™s difficulties in generating income.

Income Statement

Metric	Value	YoY Change	QoQ Change
Gross Profit	-207.00K	0.96%	-5.08%
Operating Income	-33.15M	-23.03%	-11.45%
Net Income	-29.03M	-102.54%	-4.98%
EPS	-0.84	-64.71%	-5.00%

Key Financial Ratios

Return on Assets

Weak

-0.26%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.33%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

5.44

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.08

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-4.72x

Negative earnings make P/E ratio not meaningful

Price to Book

High Premium

6.18x

Very high premium suggests asset-light business model or lofty expectations

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2026	1.43	-1.12	+18.2%	View
Q3 2025	0.00	-0.92	+0.0%	View
Q2 2025	0.00	-0.91	+0.0%	View
Q1 2025	0.00	-0.87	+0.0%	View
Q4 2024	1.21	-1.02	+0.0%	View
Q3 2024	0.00	-0.84	+0.0%	View

KALV

KalVista Pharmaceuticals

Q1 2026 Report

KalVista Pharmaceuticals Inc (KALV) QQ1 2026 Results Analysis — Early US Launch of EKTERLY Drives Modest Revenue but Funds Global Commercial Expansi...

Read full report

KALV

KalVista Pharmaceuticals

Q3 2025 Report

KalVista Pharmaceuticals Inc (KALV) Q3 2025 Financial Results Analysis: Strategic Positioning in Biotechnology...

Read full report

KALV

KalVista Pharmaceuticals

Q2 2025 Report

KalVista Pharmaceuticals Inc (KALV) Q2 2025 Financial Results: An Expense Challenge Amid Innovative Aspirations...

Read full report

KALV

KalVista Pharmaceuticals

Q1 2025 Report

KalVista Pharmaceuticals Inc (KALV) Q1 2025 Financial Results: Navigating Through Setbacks...

Read full report

KALV

KalVista Pharmaceuticals

Q4 2024 Report

KalVista Pharmaceuticals Inc (KALV) Q4 2024 Results: Analyzing Financial Performance and Strategic Outlook...

Read full report

KalVista Pharmaceuticals (KALV) Q3 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More KALV Quarterly Reports

KALV

KALV

KALV

KALV

KALV

Q3 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

KALV Full Profile

KALV Financial Statements

Earnings Calendar